Rituximab-refractory lupus nephritis successfully treated with belimumab

Clinical and Experimental Rheumatology

Volumn 34, Issue 2, 2016, Pages 355-356

  Gonzalez Echavarri, Cristina ^a   Ugarte, A ^a   Ruiz Irastorza, G ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BELIMUMAB; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; ENALAPRIL; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MEPREDNISONE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RITUXIMAB; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTHRITIS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LETTER; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; LUPUS NEPHRITIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; RITUXIMAB;

EID: 84963811649     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. BERTSIAS GK, TEKTONIDOU M, AMOURA Z et al.: Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-82
2. HAHN BH: Belimumab for systemic lupus erythematosus. N Engl J Med 2013; 368: 1528-35
3. DOOLEY MA, HOUSSIAU F, ARANOW C et al.: Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013; 22: 63-72
4. NAVARRA SV, GUZMáN RM, GALLACHER AE et al.: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebocontrolled, phase 3 trial. Lancet 2011; 377: 721-31
5. FURIE R, PETRI M, ZAMANI O et al.: A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30
6. RAMOS-CASALS M, RUIZ-IRASTORZA G, JIMé-NEZ-ALONSO J, KHAMASHTA MA: Recomendaciones sobre el uso de belimumab en el lupus eritematoso sistémico. Guía de Práctica Clínica GEAS-SEMI. Rev Clin Esp 2013; 213: 42-58
7. Van VOLLENHOVEN RF, PETRI MA, CERVERA R et al.: Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 71: 1343-9
8. DíAZ-LAGARES C, CROCA S, SANGLE S et al.: Efficacy of rituximab in 164 patients with biopsyproven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-64
9. FLIEBER E, KORSTEN P, KOZIOLEK M et al.: Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. Lupus 2013; 22: 1523-5
10. KRAAIJ T, HUIZINGA TWJ, RABELINK TJ, TENG YKO: Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology 2014; 53: 2122-4